Keyphrases
3-group
14%
5-year Survival
57%
Associated Risk Factors
14%
Classification Scheme
14%
Disease-free Survival
28%
Female Patients
14%
Lymph Node Metastasis
28%
Male Patients
14%
Metastatic Lymph Node
85%
Multivariate Analysis
14%
N2 Non-small-cell Lung Cancer
14%
Negative Lymph Node Count
14%
Negative Lymph Nodes
100%
Non-small Cell Lung Cancer (NSCLC)
100%
Non-small Cell Lung Cancer Patients
57%
Optimal Cutoff
14%
Overall Survival
42%
Prognostic Factors
14%
Prognostic Impact
14%
Prognostic Importance
14%
Prognostic Value
100%
Risk Factors
14%
Risk Stratification
14%
Survival Analysis
14%
Survival Outcomes
14%
Survival Prediction
14%
Univariate Analysis
14%
Validation Evidence
14%
Medicine and Dentistry
Disease Free Survival
25%
Lymph Node
100%
Lymph Node Metastasis
100%
Multivariate Analysis
12%
Non Small Cell Lung Cancer
100%
Overall Survival
37%
Prognostic Factor
12%
Survival Analysis
12%
Survival Rate
50%
Univariate Analysis
12%
Pharmacology, Toxicology and Pharmaceutical Science
Disease Free Survival
25%
Lymph Node Metastasis
100%
Non Small Cell Lung Cancer
100%
Overall Survival
37%
Survival Rate
50%
Immunology and Microbiology
Disease Free Survival
12%
Lymph Node
100%
Overall Survival
18%
Survival Rate
25%